Cytokinetics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.7%projected annual EPS growth
Analyst Coverage
20analysts covering
FY EPS (est.)
-$5.95next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Target Action Date for MAPLE-HCM sNDA | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
MYQORZO (aficamten) U.S. Net Product Revenue Quarterly4.8MTarget: Gradual commercial ramp-up with target of >50% preference share in oHCM by end of 2026
Unique Healthcare Providers Prescribing MYQORZO Quarterly275.0Target: Continued expansion of prescriber base beyond early adopter centers
Estimated Patients Prescribed MYQORZO Quarterly680.0Target: Accelerating patient enrollment and conversion to paid prescriptions
Cash, Cash Equivalents and Investments Quarterly1.1BTarget: Maintain sufficient runway into 2028 to support global launch and late-stage trials
Watch Items
- FDA Supplemental NDA (sNDA) Action for MAPLE-HCMTrigger: PDUFA Target Action Date of November 14, 2026Action: Monitor FDA decision on label expansion to establish aficamten as a first-line monotherapy superior to metoprolol
- European Commercial Rollout of MYQORZOTrigger: First expected launch in Germany in Q2 2026Action: Track initial sales, market access, and reimbursement negotiations in Germany and subsequent EU countries
- Phase 3 COMET-HF Trial EnrollmentTrigger: Patient enrollment expected to continue through 2026Action: Monitor enrollment progress and timeline for the confirmatory trial of omecamtiv mecarbil in HFrEF
- Phase 2 AMBER-HFpEF Trial EnrollmentAction: Track clinical progress of ulacamten in heart failure with preserved ejection fraction
Research as of 2 Sep 2026